At the 20th Congress of the European Hematology Association (EHA), Dieter Hoelzer, MD, PhD, of Goethe University Hospital, Frankfurt, Germany, discusses the possibilities of immunotherapy for the treatment of patients with acute lymphoblastic leukemia.

R.J. Agostinelli was diagnosed with acute lymphoblastic Leukemia (ALL) in the summer of 2008. After months of treatment, he is finally ready to go back to school as a fifth grader. Listen as he tells his amazing story!

Pediatric acute lymphoblastic leukemia (ALL) is a heterogeneous disease. At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Martin Schrappe, MD, PhD, from University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany, explains that there have been significant advances in the understanding of pediatric ALL subtypes and there is now a need to define the clinical importance of these subtypes.

In April 2012, 7-year-old cancer patient Emily (Emma) Whitehead became the first child to be enrolled in CTL019, a clinical trial for patients with B cell cancers such as acute lymphocytic leukemia (ALL), B cell non-Hodgkin lymphoma (NHL), and the adult disease chronic lymphocytic leukemia (CLL). Emily received this experimental treatment at The Children's Hospital of Philadelphia in April 2012 after her cancer relapsed for the second time. Her cancer has been in remission since her treatment.